MRK-409
Abandoned drug
From Wikipedia, the free encyclopedia
MRK-409, also known as MK-0343, is a GABAA receptor partial agonist.[2]
| Names | |
|---|---|
| IUPAC name
7-Cyclobutyl-3-(2,6-difluorophenyl)-6-[(2-methyl-1,2,4-triazol-3-yl)methoxy]-[1,2,4]triazolo[4,3-b]pyridazine | |
Other names
| |
| Identifiers | |
3D model (JSmol) |
|
| ChEMBL | |
| ChemSpider | |
| DrugBank | |
PubChem CID |
|
| UNII | |
CompTox Dashboard (EPA) |
|
| |
| |
| Properties | |
| C19H17F2N7O | |
| Molar mass | 397.390 g·mol−1 |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
| |
It was designed to be a non-sedative anxiolytic, however its development was halted because it produced sedation in humans.[3]
Pharmacodynamics
Despite lacking the benzodiazepine chemical structure, MRK-409 acts on the benzodiazepine binding site, it is therefore a nonbenzodiazepine.
MRK-409 binds to the α1, α2, α3 and α5 subunits of the GABAA receptor.[4]
In rats, it produces minimal to no sedation, however it produces sedation in humans at doses above 1 mg.[3][5]
See also
- ENX-102 (TPA-023B)
